In a non-public letter sent earlier this week, the US Department of Health and Human Services (HHS) recommended to the US Drug Enforcement Administration (DEA) that marijuana be re-classified
Continue Reading HHS to DEA: Marijuana Should Be Schedule III – What This Means for The Cannabis IndustrySharon Lindan Mayl
Two hemp-derived CBD bills are re-introduced despite FDA’s call for a different legislative fix
By Jarred Reiling & Sharon Lindan Mayl on
Posted in Regulatory
We’ve written previously about FDA’s denial of three petitions requesting that the agency issue a regulation that would allow cannabidiol (CBD) products to be marketed as dietary supplements. FDA…
Continue Reading Two hemp-derived CBD bills are re-introduced despite FDA’s call for a different legislative fixFDA seems willing to make room for a drug ingredient in a supplement, but what does that mean for CBD? NAC and the Drug Exclusion Clause of 201(ff)
By Sharon Lindan Mayl on
Posted in Regulatory
Section 201(ff) of the FD&C Act defines dietary supplements to exclude products that contain active drug ingredients (ie, ingredients that have been approved under section 505 of the…
Continue Reading FDA seems willing to make room for a drug ingredient in a supplement, but what does that mean for CBD? NAC and the Drug Exclusion Clause of 201(ff)